Clinical Trial CTSUGIC80802-M


Phase III randomized study of sorafenib (IND 69896, NSC 724772) plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)

Principal Investigator(s)

John Murray


  • Protocol No. CTSUGIC80802-M
  • Open Date: 12/07/2010
  • Staging: Phase III
  • Age Group: Adults
  • Scope: National
  • Objective:
  • Disease Sites:
  • Therapies: Chemotherapy - cytotoxic; Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: BAY 43-9006 (Sorafenib); Sorafenib (Nexavar)
  • Participating Institutions: Baptist Hospital; Meharry Medical College
  • Secondary Protocol No: Not Specified



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.